Murine syngeneic tumor model

The syngeneic model involves inoculation of a tumor cell line of homologous background origin into an immunocompetent inbred mouse. The recipient mice have an intact murine immune system that is fully immunologically active, and this immune system is compatible with the syngeneic transplanted tumor tissue, maximally mimicking the tumor microenvironment. The downside is that the transplanted mouse tissue may not fully represent the complexity of human tumors in the clinical setting. CIR Biopharma has developed a series of mouse homologous tumor models to meet the needs of our clients for new drug discovery and development. Currently, CIR Biopharma team has developed models in various tumor types such as colorectal cancer, liver cancer, pancreatic cancer, lung cancer, bladder cancer, melanoma, and lymphoma et al.